Abstract: The invention relates to a method for accelerating the time to flowering of a plant and/or for increasing the amount of flowers and/or fruits produced by said plant of the family rubiaceae, the method comprising providing a plant seed or plant part which is capable of regeneration, cultivating the same to a stage in which a cultivated shoot is obtained that comprises a fork from which an orthotropic shoot and at least two plagiotropic branches have developed, pruning the cultivated shoot at said fork by removing at least the orthotropic shoot and maintaining at least one plagiotropic branch to obtain a pruned shoot, cultivating the pruned shoot until flowers form on the at least one plagiotropic branch to obtain a flowered shoot.

Abstract: A computer-implemented method includes receiving a series of measurements of distances generated, from a plurality of different positions each time, by a detection system operating by: transmitting a wave; receiving waves reflected by the environment; determining the distances by calculating differences between the wave transmission time and the time of reception of the reflected waves; generating, based on the series of distance measurements, a synthetic image representing the distances from the environment relative to a reference position; for each focal distance of a plurality of focal distances: generating, from the series of distance measurements or the synthetic image, a synthetic image that is focused at the focal distance, by applying compensation for penumbra effects; and detecting the presence of an object in the focused synthetic image.

Abstract: The present invention provides composition kits and methods for treating cancer in a human by immunotherapy using successive doses of CAR-T cells with no or reduced anamnestic immune reaction in one individual (P).

Abstract: The present invention pertains to engineered immune cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered immune cells of the present invention are characterized in that at least one gene selected from a gene encoding GCN2 and a gene encoding PRDM1 is inactivated or repressed. Such modified Immune cells are resistant to an arginine and/or tryptophan depleted microenvironment caused by, e.g., tumor cells, which makes the immune cells of the invention particularly suitable for immunotherapy. The invention opens the way to standard and affordable adoptive immunotherapy strategies using immune cells for treating different types of malignancies.

Abstract: The present invention provides composition kits and methods for treating cancer in a human by immunotherapy using successive doses of CAR-T cells with no or reduced anamnestic immune reaction in one individual (P).

Abstract: The present invention provides composition kits and methods for treating cancer in a human by immunotherapy using successive doses of CAR-T cells with no or reduced anamnestic immune reaction in one individual (P).

Abstract: Ejection system for a vehicle emergency exit ejection system for a vehicle emergency exit, the emergency exit extending along a base surface and being designed to cooperate in a mounted position with a receiving frame of the vehicle, the ejection system including a retaining element and a locking mechanism designed to cooperate with the retaining element in a locking configuration in which a movable part of the locking mechanism prevents a relative movement of the retaining element and the locking mechanism in a direction of ejection of the emergency exit which is transversal to the base surface, the movable part being configured to be moved in a closing plane that extends transversally to the base surface and an ejection configuration in which the locking mechanism is capable of moving in the direction of ejection relative to the retaining element.

Abstract: The present invention pertains to engineered immune cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered immune cells of the present invention are characterized in that at least one gene selected from a gene encoding GCN2 and a gene encoding PRDM1 is inactivated or repressed. Such modified Immune cells are resistant to an arginine and/or tryptophan depleted microenvironment caused by, e.g., tumor cells, which makes the immune cells of the invention particularly suitable for immunotherapy. The invention opens the way to standard and affordable adoptive immunotherapy strategies using immune cells for treating different types of malignancies.

Abstract: The present invention pertains to engineered immune cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered immune cells of the present invention are characterized in that at least one gene selected from a gene encoding GCN2 and a gene encoding PRDM1 is inactivated or repressed. Such modified Immune cells are resistant to an arginine and/or tryptophan depleted microenvironment caused by, e.g., tumor cells, which makes the immune cells of the invention particularly suitable for immunotherapy. The invention opens the way to standard and affordable adoptive immunotherapy strategies using immune cells for treating different types of malignancies.

Abstract: The present invention relates to a TCR KO—or TCR KO and dCK KO—engineered immune cells expressing a Chimeric Antigen Receptors (CAR) specific for CD123 that is a recombinant chimeric protein able to redirect immune cell specificity and reactivity toward CD123-expressing cells, and more particularly in which extracellular ligand binding is a scFV derived from a CD123 monoclonal antibody, conferring specific immunity against CD123 positive cells. The engineered immune cells endowed with such CD123 CARs are particularly suited for treating relapse refractory AML and blastic plasmacytoid dendritic cell neoplasm and for use as a treatment before bone marrow transplantation.

Abstract: The present invention pertains to engineered immune cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered immune cells of the present invention are characterized in that at least one gene selected from a gene encoding GCN2 and a gene encoding PRDM1 is inactivated or repressed. Such modified Immune cells are resistant to an arginine and/or tryptophan depleted microenvironment caused by, e.g., tumor cells, which makes the immune cells of the invention particularly suitable for immunotherapy. The invention opens the way to standard and affordable adoptive immunotherapy strategies using immune cells for treating different types of malignancies.